{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:43:22Z","timestamp":1792640602488,"version":"4.5.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The immunocompromised population was disproportionately affected by the severe acute respiratory syndrome coronavirus 2 pandemic. However, these individuals were largely excluded from clinical trials of vaccines, monoclonal antibodies, and small molecule antivirals. Although the community of scientists, clinical researchers, and funding agencies have proven that these therapeutics can be made and tested in record time, extending this progress to vulnerable and medically complex individuals from the start has been a missed opportunity. Here, we advocate that it is paramount to plan for future pandemics by investing in specific clinical trial infrastructure for the immunocompromised population to be prepared when the need arises.<\/jats:p>","DOI":"10.1093\/cid\/ciae308","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T20:44:59Z","timestamp":1717188299000},"page":"1018-1023","source":"Crossref","is-referenced-by-count":29,"title":["How Immunocompromised Hosts Were Left Behind in the Quest to Control the COVID-19 Pandemic"],"prefix":"10.1093","volume":"79","author":[{"given":"Michael","family":"Boeckh","sequence":"first","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington ,","place":["USA"]},{"name":"Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington , Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A","family":"Pergam","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington ,","place":["USA"]},{"name":"Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington , Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajit P","family":"Limaye","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington , Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Englund","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington , Seattle, Washington ,","place":["USA"]},{"name":"Seattle Children's Research Institute , Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Corey","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington ,","place":["USA"]},{"name":"Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington , Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A","family":"Hill","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington ,","place":["USA"]},{"name":"Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington , Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,3]]},"reference":[{"key":"2024101519050825700_ciae308-B1","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.immuni.2022.09.006","article-title":"SARS-CoV-2 in immunocompromised individuals","volume":"55","author":"DeWolf","year":"2022","journal-title":"Immunity"},{"key":"2024101519050825700_ciae308-B2","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1093\/infdis\/jiad174","article-title":"COVID-19 vaccination in patients with cancer and patients receiving HSCT or CAR-T therapy: immune response, real-world effectiveness, and implications for the future","volume":"228","author":"Hall","year":"2023","journal-title":"J Infect Dis"},{"key":"2024101519050825700_ciae308-B3","doi-asserted-by":"crossref","first-page":"104577","DOI":"10.1016\/j.jcv.2020.104577","article-title":"Clinical predictors and timing of cessation of viral RNA shedding in patients with COVID-19","volume":"130","author":"Corsini Campioli","year":"2020","journal-title":"J Clin Virol"},{"key":"2024101519050825700_ciae308-B4","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1093\/cid\/ciac077","article-title":"Prolonged shedding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at high viral loads among hospitalized immunocompromised persons living with human immunodeficiency virus (HIV), South Africa","volume":"75","author":"Meiring","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024101519050825700_ciae308-B5","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1056\/NEJMsb2104756","article-title":"SARS-CoV-2 variants in patients with immunosuppression","volume":"385","author":"Corey","year":"2021","journal-title":"N Engl J Med"},{"key":"2024101519050825700_ciae308-B6","doi-asserted-by":"crossref","first-page":"R918","DOI":"10.1016\/j.cub.2021.06.049","article-title":"The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic","volume":"31","author":"Otto","year":"2021","journal-title":"Curr Biol"},{"key":"2024101519050825700_ciae308-B7","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.3201\/eid2608.191493","article-title":"Analysis of MarketScan data for immunosuppressive conditions and hospitalizations for acute respiratory illness, United States","volume":"26","author":"Patel","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"2024101519050825700_ciae308-B8","author":"European Cancer Patient Coalition, European Society for Organ Transplantation, UNION Therapeutics","year":"2023"},{"key":"2024101519050825700_ciae308-B9","doi-asserted-by":"crossref","first-page":"109097","DOI":"10.1016\/j.clim.2022.109097","article-title":"COVID-19-related health outcomes in people with primary immunodeficiency: a systematic review","volume":"243","author":"Drzymalla","year":"2022","journal-title":"Clin Immunol"},{"key":"2024101519050825700_ciae308-B10","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S2352-3026(20)30429-4","article-title":"Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study","volume":"8","author":"Sharma","year":"2021","journal-title":"Lancet Haematol"},{"key":"2024101519050825700_ciae308-B11","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1038\/s41375-021-01302-5","article-title":"COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey","volume":"35","author":"Ljungman","year":"2021","journal-title":"Leukemia"},{"key":"2024101519050825700_ciae308-B12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/TP.0000000000003523","article-title":"COVID-19 and solid organ transplantation: a review article","volume":"105","author":"Azzi","year":"2021","journal-title":"Transplantation"},{"key":"2024101519050825700_ciae308-B13","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1200\/JCO.20.01307","article-title":"Chemotherapy and COVID-19 outcomes in patients with cancer","volume":"38","author":"Jee","year":"2020","journal-title":"J Clin Oncol"},{"key":"2024101519050825700_ciae308-B14","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3390\/vaccines10050800","article-title":"Vaccination for the prevention of infection among immunocompromised patients: a concise review of recent systematic reviews","volume":"10","author":"See","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"2024101519050825700_ciae308-B15","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.cmi.2021.09.036","article-title":"Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review","volume":"28","author":"Galmiche","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2024101519050825700_ciae308-B16","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.vaccine.2008.10.087","article-title":"Vaccine-induced enhancement of viral infections","volume":"27","author":"Huisman","year":"2009","journal-title":"Vaccine"},{"key":"2024101519050825700_ciae308-B17","doi-asserted-by":"crossref","first-page":"A646","DOI":"10.1016\/j.chest.2022.08.506","article-title":"Vaccine-induced antibody dependent enhancement in COVID-19","volume":"162","author":"Sridhar","year":"2022","journal-title":"Chest"},{"key":"2024101519050825700_ciae308-B18","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1016\/j.vaccine.2016.11.015","article-title":"Vaccination of special populations: protecting the vulnerable","volume":"34","author":"Doherty","year":"2016","journal-title":"Vaccine"},{"key":"2024101519050825700_ciae308-B19","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jtct.2022.10.010","article-title":"Frequently asked questions on coronavirus disease 2019 vaccination for hematopoietic cell transplantation and chimeric antigen receptor T-cell recipients from the American Society for Transplantation and Cellular Therapy and the American Society of Hematology","volume":"29","author":"Khawaja","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"2024101519050825700_ciae308-B20","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/cid\/ciab882","article-title":"Infectious Diseases Society of America guidelines on the treatment and management of patients with coronavirus disease 2019 (COVID-19)","volume":"74","author":"Bhimraj","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024101519050825700_ciae308-B21","doi-asserted-by":"crossref","first-page":"5624","DOI":"10.1182\/bloodadvances.2023010349","article-title":"Attenuated immunogenicity of SARS-CoV-2 vaccines and risk factors in stem cell transplant recipients: a meta-analysis","volume":"7","author":"Meejun","year":"2023","journal-title":"Blood Adv"},{"key":"2024101519050825700_ciae308-B22","doi-asserted-by":"crossref","first-page":"e2251974","DOI":"10.1001\/jamanetworkopen.2022.51974","article-title":"Rapid development of an integrated network infrastructure to conduct phase 3 COVID-19 vaccine trials","volume":"6","author":"Mena Lora","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2024101519050825700_ciae308-B23","author":"US Food & Drug Administration","year":"2021"},{"key":"2024101519050825700_ciae308-B24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ijid.2023.06.021","article-title":"Monoclonal antibodies as COVID-19 prophylaxis therapy in immunocompromised patient populations","volume":"134","author":"Cowan","year":"2023","journal-title":"Int J Infect Dis"},{"key":"2024101519050825700_ciae308-B25","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1001\/jama.2022.2832","article-title":"Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial","volume":"327","author":"Gupta","year":"2022","journal-title":"JAMA"},{"key":"2024101519050825700_ciae308-B26","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S2213-2600(22)00215-6","article-title":"Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial","volume":"10","author":"ACTIV-3\u2013Therapeutics for Inpatients with COVID-19 (TICO) Study Group","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2024101519050825700_ciae308-B27","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41579-022-00809-7","article-title":"SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies","volume":"21","author":"Cox","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"2024101519050825700_ciae308-B28","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.cmi.2022.05.005","article-title":"Immunocompromised patients have been neglected in COVID-19 trials: a call for action","volume":"28","author":"Tr\u00f8seid","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2024101519050825700_ciae308-B29","doi-asserted-by":"crossref","first-page":"101965","DOI":"10.1016\/j.eclinm.2023.101965","article-title":"Vaccines and therapeutics for immunocompromised patients with COVID-19","volume":"59","author":"Shoham","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2024101519050825700_ciae308-B30","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1093\/cid\/ciad460","article-title":"Remdesivir reduced mortality in immunocompromised patients hospitalized for COVID-19 across variant waves: findings from routine clinical practice","volume":"77","author":"Mozaffari","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2024101519050825700_ciae308-B31","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s15010-022-01959-9","article-title":"Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial","volume":"51","author":"Johnson","year":"2023","journal-title":"Infection"},{"key":"2024101519050825700_ciae308-B32","doi-asserted-by":"crossref","first-page":"e2336678","DOI":"10.1001\/jamanetworkopen.2023.36678","article-title":"Nirmatrelvir-ritonavir and COVID-19 mortality and hospitalization among patients with vulnerability to COVID-19 complications","volume":"6","author":"Dormuth","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2024101519050825700_ciae308-B33","article-title":"Human cytomegalovirus mRNA-1647 vaccine candidate elicits potent and broad neutralization and higher antibody-dependent cellular cytotoxicity responses than the gB\/MF59 vaccine","author":"Hu","journal-title":"J Infect Dis"},{"key":"2024101519050825700_ciae308-B34","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.3389\/fimmu.2018.01632","article-title":"Herpes zoster and immunogenicity and safety of zoster vaccines in transplant patients: a narrative review of the literature","volume":"9","author":"Wang","year":"2018","journal-title":"Front Immunol"},{"key":"2024101519050825700_ciae308-B35","author":"GlaxoSmithKine","year":"2021"},{"key":"2024101519050825700_ciae308-B36","doi-asserted-by":"crossref","first-page":"105152","DOI":"10.1016\/j.jcv.2022.105152","article-title":"Correlation of initial upper respiratory tract viral burden with progression to lower tract disease in adult allogeneic hematopoietic cell transplant recipients","volume":"150\u2013151","author":"Ogimi","year":"2022","journal-title":"J Clin Virol"},{"key":"2024101519050825700_ciae308-B37","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S1473-3099(23)00493-0","article-title":"Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial","volume":"24","author":"Schilling","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2024101519050825700_ciae308-B38","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jiac.2023.10.022","article-title":"Dual anti-viral treatment for persistent COVID-19 in immunocompromised hemato-oncological patients is associated with a favorable prognosis and minor side effects","volume":"30","author":"Meijer","year":"2023","journal-title":"J Infect Chemother"},{"key":"2024101519050825700_ciae308-B39","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s15010-023-02125-5","article-title":"Early combination therapy of COVID-19 in high-risk patients","volume":"52","author":"Orth","year":"2023","journal-title":"Infection"},{"key":"2024101519050825700_ciae308-B40","doi-asserted-by":"crossref","first-page":"101017","DOI":"10.1016\/j.xcrm.2023.101017","article-title":"Robust SARS-CoV-2T cell responses with common TCRalphabeta motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells","volume":"4","author":"Nguyen","year":"2023","journal-title":"Cell Rep Med"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae308\/58599663\/ciae308.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/79\/4\/1018\/59764801\/ciae308.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/79\/4\/1018\/59764801\/ciae308.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T15:05:59Z","timestamp":1729004759000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/79\/4\/1018\/7686576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,6,3]]},"published-print":{"date-parts":[[2024,10,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae308","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10,15]]},"published":{"date-parts":[[2024,6,3]]}}}